Compare PRSO & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSO | PLUR |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 12.5M |
| IPO Year | 2000 | 2026 |
| Metric | PRSO | PLUR |
|---|---|---|
| Price | $0.30 | $1.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 11.7M | 62.2K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.23 | 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,573,000.00 | $1,016,000.00 |
| Revenue This Year | N/A | $902.46 |
| Revenue Next Year | $191.73 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.99 | N/A |
| 52 Week Low | $0.28 | $0.85 |
| 52 Week High | $2.10 | $4.12 |
| Indicator | PRSO | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 36.98 | 40.32 |
| Support Level | N/A | $0.88 |
| Resistance Level | $0.46 | $1.85 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 10.38 | 0.00 |
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.